Physician profile
Rawinder Parmar
NPI 1578958641
$765.65
in general payments reported to CMS, 2019-2025
11 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $418 · 2023: $119 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $232.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $214.01 | 2021-2023 | Trulance, Xifaxan |
| Novo Nordisk INC | $161.69 | 2021-2023 | Wegovy |
| Baxter Healthcare | $113.02 | 2025 | Tisseel |
| Glaxosmithkline, LLC. | $109.31 | 2022 | |
| Abbvie INC. | $62.15 | 2021-2023 | |
| Organon LLC | $25.78 | 2022 | |
| Amarin Pharma, INC. | $18.93 | 2021 | |
| Mylan Specialty L.P. | $18.53 | 2023 | Yupelri |
| Sanofi-Aventis U.S. LLC | $14.49 | 2022 | |
| Nestle Healthcare Nutrition INC. | $14.19 | 2021 | |
| Lilly USA, LLC | $13.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rawinder Parmar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.